<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01138956</url>
  </required_header>
  <id_info>
    <org_study_id>VLNAC</org_study_id>
    <nct_id>NCT01138956</nct_id>
  </id_info>
  <brief_title>Immune Response of Visceral Leishmaniasis PatientsTreated With Antimonial Plus N-Acetylcysteine</brief_title>
  <acronym>VLNAC</acronym>
  <official_title>Study for Evaluation of the Immune Response of Visceral Leishmaniasis Patients Treated With Antimonial Pentavalent Associated to N-Acetylcysteine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitário Professor Edgard Santos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitário Professor Edgard Santos</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the immune and therapeutic responses of visceral
      leishmaniasis patients using N-acetylcysteine (NAC) as an adjuvant therapy to pentavalent
      antimony.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study we intend to evaluate the immune and therapeutic responses of patients with
      visceral leishmaniasis N-acetylcysteine (NAC) as an adjuvant to standard treatment with
      pentavalent antimony, compared to treatment with antimonial only through a blind randomized
      clinical trial. Our hypothesis is that patients treated with NAC associated with pentavalent
      atimonial have a rapid changing of the immune responses, towards TH1, and clinical
      improvement when compared to patients who will use only the standard treatment
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient recovery from the visceral leishmaniasis after treatment</measure>
    <time_frame>6 months</time_frame>
    <description>The cure is defined in the patient with reduced spleen and liver. Absence of fever for more than 15 days after treatment, weight gain, normalization of globulins and resolution of leukopenia and anemia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune response of visceral leishmaniasis patients after proposed treatment</measure>
    <time_frame>one year</time_frame>
    <description>Evaluation of the Immune response: peripheral blood mononuclear cells of patients are being obtained in ficoll-Hypaque gradient and stimulated in vitro with soluble antigen of L. chagasi to evaluate the production of cytokines (IFN-g, TNF-a. IL-10, TGF-b) before treatment, 15, 45, 180 and 360 days afterwards.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Visceral Leishmaniasis</condition>
  <condition>Immune Response</condition>
  <condition>Treatment</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pentavalent antimonial, 20mg/kg/day, 28 days, IV, plus N-acetylcysteine (NAC), effervescent tablets of 600mg, tid, po.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pentavalent antimonial, 20mg/kg/day, 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine</intervention_name>
    <description>N-acetylcysteine (NAC), effervescent tablets of 600mg, tid, po, 28 days</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentavalent antimonial</intervention_name>
    <description>Pentavalent antimonial, 20mg/kg/day, 28 days, IV</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 2 to 50 years

          -  Diagnosis of visceral leishmaniasis

        Exclusion Criteria:

          -  Other acute or chronic diseases

          -  Use of immunosuppressive drugs

          -  AIDS

          -  History of allergy to NAC and/or pentavalent antimony
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roque P Almeida, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitário</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roque P Almeida, MD, PhD</last_name>
    <phone>5579-21051806</phone>
    <email>roquepacheco@uol.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Enaldo V Melo, MD</last_name>
    <phone>5579-21051700</phone>
    <email>evm.estatistica@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Aracaju</city>
        <state>Sergipe</state>
        <zip>49060-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roque P Almeida, MD, PhD</last_name>
      <phone>5579-21051806</phone>
      <email>roquepacheco@uol.com.br</email>
    </contact>
    <contact_backup>
      <last_name>Enaldo V Melo, MD</last_name>
      <phone>5579-21051700</phone>
      <email>evm.estatistica@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Angela M Silva, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2010</study_first_submitted>
  <study_first_submitted_qc>June 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2010</study_first_posted>
  <last_update_submitted>June 7, 2010</last_update_submitted>
  <last_update_submitted_qc>June 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Roque Pacheco de Almeida</name_title>
    <organization>Universidade Federal de Sergipe</organization>
  </responsible_party>
  <keyword>Visceral leishmaniasis</keyword>
  <keyword>N-acetylcysteine</keyword>
  <keyword>Antimony</keyword>
  <keyword>Immune response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Visceral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

